Rematib 15 mg (generic Upadacitinib)

Description

Dr. Daria Kwaśniewska ESMO Certified Consultant Medical Oncologist

Reviewed June 2026

⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. A valid physician prescription is mandatory before any order is processed.

Is Rematib 15 mg right for your situation?

Review these criteria with your doctor before enquiring

✔ You may be a candidate if

✓Moderate-to-severe active rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis with inadequate response to prior therapies
✓Moderate-to-severe atopic dermatitis in adults or adolescents 12+ uncontrolled by topical therapy
✓Moderate-to-severe active ulcerative colitis
✓Need a generic alternative to Rinvoq® (AbbVie)

✖ May NOT be suitable if

✗Active serious infection (including tuberculosis) — screening mandatory before starting
✗History of venous thromboembolism or major cardiovascular events
✗Pregnant or planning pregnancy
✗Age 50+ with cardiovascular risk factors — requires careful benefit/risk discussion with your doctor

Check Availability & Pricing

Prescription required · Named Patient Program · Worldwide shipping

💬 WhatsApp: +880 130 449 8958 ✉ Email: info@medsforcancer.com

🛡 WHO-GMP Certified · Prescription verified · Express dispatch

What is Rematib 15 mg?

Rematib 15 mg is a generic extended-release formulation of Upadacitinib — a selective JAK-1 inhibitor — manufactured by Drug International Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 15 mg of upadacitinib in an extended-release formulation, the same active molecule found in Rinvoq® (AbbVie), and is dispensed under the Named Patient Program for patients requiring an affordable, quality-assured alternative.

Upadacitinib is a small molecule generic — not a biosimilar. Unlike biologics, it does not require injection and does not trigger immune responses related to protein-based medicine.

Generic name	Upadacitinib
Reference brand	Rinvoq® (AbbVie)
Manufacturer	Drug International Ltd.
Standard	WHO-GMP Certified
Drug class	JAK-1 Selective Inhibitor
Dosage form	Extended-release tablet — 15 mg
Pack size	30 tablets per pack
Route	Oral · once daily, with or without food
Prescription	Required — physician only

How Upadacitinib Works

In autoimmune conditions like rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis, an overactive Janus kinase (JAK) signalling pathway drives chronic inflammation, causing joint damage, skin inflammation, and systemic symptoms.

Upadacitinib selectively inhibits JAK-1 — the specific kinase most responsible for inflammatory cytokine signalling in autoimmune disease — with greater selectivity than older JAK inhibitors. This targeted inhibition reduces the production of inflammatory cytokines (IL-6, IL-12, IL-23, interferons) without broadly suppressing the immune system. In the SELECT-COMPARE trial, upadacitinib demonstrated superior ACR50 response versus adalimumab (Humira) in rheumatoid arthritis. NCCN and ACR guidelines include upadacitinib as a recommended advanced therapy option across approved autoimmune indications.

What to Expect: First 30 Days

Upadacitinib typically shows faster onset than biologics — many patients notice symptomatic improvement within the first 2–4 weeks.

Before starting: TB screening, blood counts, liver function, and lipid panel are required. Live vaccines must be completed before initiating therapy.
Weeks 1–2: Many patients notice early reduction in joint pain, stiffness, and skin symptoms within the first 1–2 weeks. This faster onset is one of the practical advantages of JAK inhibitors over biologics.
Weeks 3–4: Blood counts and lipid levels are rechecked. Your doctor will assess response and confirm continued treatment is appropriate. Full response assessment is typically conducted at 12 weeks.

Side Effects

JAK inhibitors as a class carry important boxed warnings around infection, malignancy, cardiovascular events, and thrombosis that require patient awareness and monitoring.

Common · Usually Manageable

Upper respiratory tract infections
Nausea
Headache
Acne / folliculitis
Elevated cholesterol (LDL)
Herpes zoster reactivation

Serious · Report Immediately

Serious infections (including opportunistic)
Venous thromboembolism (DVT/PE)
Major cardiovascular events (MACE)
Malignancy (lymphoma, other cancers)
Hepatotoxicity

⚠ Call your doctor immediately if you experience:

Fever, chills, or signs of serious infection
Sudden leg swelling/pain, chest pain, or breathlessness (possible clot)
Yellowing of skin or eyes (possible liver injury)

How to Take Rematib 15 mg

Standard dose: 15 mg once daily for most indications · 30 mg once daily for atopic dermatitis and ulcerative colitis induction (physician-adjusted). With or without food; swallow whole — do not crush or chew the extended-release tablet.

1
Once daily at the same time — with or without food. The extended-release formulation relies on the tablet remaining intact for correct drug delivery.
2
Swallow whole with water. Never crush, split, or chew — this destroys the extended-release mechanism and changes drug release timing.
3
Do not start if you have an active infection — confirm with your doctor that you are infection-free and TB screening is complete before beginning.
4
If you miss a dose, take it as soon as you remember the same day. Skip if it is nearly time for the next dose.
5
Storage: room temperature, away from moisture and light.

Caregiver Guidance

♥
Watch for infection signs — upadacitinib suppresses part of the immune system. Any fever, unusual fatigue, or signs of infection should be reported promptly, as infections can become serious faster.
♥
Track blood test appointments — lipid panels and liver function need monitoring, especially in the first few months.
♥
Remind about live vaccines — live vaccines cannot be given while on upadacitinib. Ensure all necessary vaccinations are completed before starting.

If the Medicine Stops Working

Loss of response to upadacitinib may occur over time. If disease activity returns or worsens despite adequate dosing, your doctor will typically reassess — options may include dose optimisation, switching to a different JAK inhibitor, adding or switching to a biologic agent, or combination therapy strategies, depending on the specific indication and prior treatment history.

Frequently Asked Questions

Is Rematib a biosimilar?

No. Rematib (upadacitinib) is a generic small-molecule drug, not a biosimilar. Biosimilars are copies of large biological molecules (proteins) that require complex manufacturing and regulatory comparability testing. Upadacitinib is a chemically synthesised small molecule — its generic version contains exactly the same active chemical compound as Rinvoq, produced to WHO-GMP quality standards.

Why can’t I crush or chew the tablet?

Rematib is formulated as an extended-release (XR) tablet, which means the tablet’s outer matrix controls drug release gradually over 24 hours. Crushing or chewing destroys this mechanism and releases all 15 mg of upadacitinib at once, exposing you to a much higher peak drug level than intended. This can increase the risk of side effects and reduce the duration of the therapeutic effect.

How long does it take for upadacitinib to work?

Many patients notice symptomatic improvement within the first 2 weeks, particularly for joint pain, stiffness, and morning symptoms. This faster onset is one of JAK inhibitors’ advantages over biologics. Full response is typically assessed at 12 weeks — if adequate response is not achieved by that point, your doctor will review the treatment plan.

Is TB screening really necessary before starting?

Yes, and this is mandatory — not optional. JAK inhibitors including upadacitinib can cause latent TB to reactivate. A tuberculin skin test or IGRA (interferon gamma release assay) blood test must be completed and confirmed negative (or latent TB treated) before starting. Never begin upadacitinib without this being confirmed by your doctor.

Can I take Rematib if I am over 50 with cardiovascular risk?

This is a critical discussion to have with your doctor. Post-market safety data from the ORAL Surveillance trial showed increased cardiovascular events and malignancy risk with tofacitinib (a related JAK inhibitor) in patients over 50 with cardiovascular risk factors. Similar precautions apply to upadacitinib. Your doctor will weigh these risks against the benefits of treatment for your specific situation before prescribing.

How do I order Rematib through Meds For Cancer?

Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your physician’s prescription. Our team will verify the prescription, confirm availability and pricing, and arrange secure international shipping under the Named Patient Program.

🛡 Named Patient Program — Regulatory Framework

Meds For Cancer operates as a Named Patient Program (NPP) facilitator. Under this framework, WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid prescription, in countries where the branded product is unavailable or unaffordable.

This service does not constitute retail pharmacy dispensing. A prescription review is mandatory before any order is processed.

Clinical References

Fleischmann R, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis (SELECT-COMPARE). Ann Rheum Dis 2019;78:1116–1123.
Guttman-Yassky E, et al. Upadacitinib for moderate-to-severe atopic dermatitis (Measure Up 1 and 2). Lancet 2021;397:2151–2168.
FDA Prescribing Information: Rinvoq (upadacitinib). AbbVie, 2023.
NCCN Clinical Practice Guidelines in Oncology: Dermatology. V1.2026.